Silencing of the metastasis-linked gene, AEG-1, using siRNA-loaded cholamine surface-modified gelatin nanoparticles in the breast carcinoma cell line MCF-7

Abozeid, Salma M.; Hathout, Rania M.; Abou-Aisha, Khaled

doi:10.1016/j.colsurfb.2016.05.066

Cited by 46 publications

(29 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer is one of the leading causes of death worldwide and its effective treatment is therefore the focus of research supported by charities, governments and industry (Abozeid et al, 2016). While traditional anticancer drug delivery systems can be effective in certain circumstances, the use of novel drug delivery systems that maximize the therapeutic efficacy of the drugs delivered, and potentially overcome resistance mechanisms and any associated side-effects of the therapeutics to be delivered is particularly appealing (Song et al, 2017).…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Dual stimuli-responsive polypyrrole nanoparticles for anticancer therapy

Hathout

Metwally

El-Ahmady

et al. 2018

Journal of Drug Delivery Science and Technology

Self Cite

View full text Add to dashboard Cite

We report the development of dual stimuli-responsive nanoparticles with potential for anticancer therapy. The nanoparticles are composed of a conjugated polymer (polypyrrole, PPY) loaded with an anticancer drug (allicin), and were characterized by a variety of Electrochemical polymerization is appealing because it is cheap, reliable and green (Fonner et al., 2008;Balint et al., 2014); moreover, it is easy to load the polymer with a negatively charged drug (dopant) during the electrochemical polymerization. Hundreds of different anticancer drugs exist of both natural and synthetic origins (Borden et al. 1999;Curt et al.,

show abstract

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Dual stimuli-responsive polypyrrole nanoparticles for anticancer therapy

Hathout

Metwally

El-Ahmady

et al. 2018

Journal of Drug Delivery Science and Technology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Rationale of the choice of the type of the used gelatin Gelatin A (isoelectric point: 7-9) was the type of gelatin that was used in this study as it is more positively charged at the physiological pH than gelatin B (isoelectric point: 4.8-5), 17 which renders it more attracted to negatively charged entities 18 or bilayers such as those composed of phosphatidyl choline in absence/presence of cholesterol.…”

Section: Resultsmentioning

confidence: 99%

Gelatinized‐core liposomes: Toward a more robust carrier for hydrophilic molecules

Hathout

Gad

Metwally

2017

J Biomedical Materials Res

Self Cite

View full text Add to dashboard Cite

The use of liposomes as a delivery system for hydrophobic and hydrophilic drugs is well recognized. However, they possess several limitations that remained unresolved, including stability problems, low entrapment of the hydrophilic drugs, and the subsequent rapid release. This study introduces a novel approach to incorporate gelatin in the liposomal core to overcome these limitations. A rheological study was conducted to select suitable masses of the gelatin used in the liposomal formulations. Moreover, a full-factorial experimental design was utilized to compare the newly produced gel-core liposomes to the conventional liposomes with respect to the amount of a model hydrophilic molecule loading. An advanced machine learning method, namely, artificial neural networks was utilized to capture the effects of gelatin and cholesterol incorporation in the liposomes on the entrapment efficiency. The results revealed the successful preparation of the novel vesicles and their superiority over the conventional liposomes in drug loading, sustaining the drug release and stability which pose the newly introduced liposomal system as a successful delivery carrier for hydrophilic molecules and drugs. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 3086-3092, 2017.

show abstract

“…40 It should be noted that the delivery of other chemotherapeutic drugs, including simvastatin using lipid nanoencapsulation, 41 and cholamine surface-modified gelatin NPs for siRNA delivery have also shown encouraging efficacy. 42 Furthermore, the release of CG-1521 from the NPs at more acidic pH suggests that CG-NPs are most likely to release the drug in tumor microenvironment and early endosomes.…”

Section: Discussionmentioning

confidence: 99%

<p>Starch nanoparticles for delivery of the histone deacetylase inhibitor CG-1521 in breast cancer treatment</p>

Alp¹,

Damkaci²,

Güven³

et al. 2019

IJN

View full text Add to dashboard Cite

Background:The efficacy of epigenetic drugs, such as histone deacetylase inhibitors, is often diminished by poor aqueous solubility resulting in limited bioavailability and a low therapeutic index. To overcome the suboptimal therapeutic index, we have developed a biocompatible starch nanoparticle formulation of CG-1521, a histone deacetylase inhibitor in preclinical development for hard-to-treat breast cancers, which improves its bioavailability and half-life. Methods: The physicochemical parameters (size, zeta potential, morphology, loading, and release kinetics) of these nanoparticles (CG-NPs) have been optimized and their cytotoxic and apoptotic capacities measured in MCF-7 breast cancer cell line. The mechanism of action of the encapsulated drug was compared with the free drug at molecular level. Results: We show that encapsulation of CG-1521 substantially reduces the release rate of drug and provides a significantly enhanced cytotoxic ability of nanoparticles compared with equivalent dose of free CG-1521. CG-NPs induced cell cycle arrest and significant apoptosis in MCF-7 cells in vitro. The biological action of encapsulated drug has the similar impact with free drug on gene expression. Conclusion: The findings suggest that encapsulation of CG-1521 into starch nanoparticles can improve drug delivery of histone deacetylase inhibitors for breast cancer therapy without interfering with the mechanism of action of the drug.

show abstract

Silencing of the metastasis-linked gene, AEG-1, using siRNA-loaded cholamine surface-modified gelatin nanoparticles in the breast carcinoma cell line MCF-7

Cited by 46 publications

References 21 publications

Dual stimuli-responsive polypyrrole nanoparticles for anticancer therapy

Dual stimuli-responsive polypyrrole nanoparticles for anticancer therapy

Gelatinized‐core liposomes: Toward a more robust carrier for hydrophilic molecules

<p>Starch nanoparticles for delivery of the histone deacetylase inhibitor CG-1521 in breast cancer treatment</p>

Contact Info

Product

Resources

About